

December 12, 2002

Office of Special Nutritionals (HFS-450) Center for Food Safety and Applied Nutrition U. S. Food and Drug Administration 5100 Paint Branch Parkway College Park, MD 20740-3835

RE:

Label Claims/Disclaimers

Dear Sir/Madam:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product.

COMPANY	PRODUCT NAME	DIETARY INGREDIENTS	<u>STATEMENTS</u>
Enzymatic Therapy, Inc.	Acidophilus Pearls™	Proprietary Probiotic Blend Lactobacillus acidophilus and Bifdobacterium longum	Unique "pearl" delivery system provides L. acidophilus and B. longum to increase healthy intestinal flora.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

Robert Doster

Title: Senior Vice President of Scientific Affairs

Date: 12/12/02

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs at (920) 406-3608.

Michael P. Devereux Chief Financial Officer 975 0162

LET 11305

825 Challenger Drive

Green Bay, WI 54311-8328

Ph: 920-469-1313

Fax: 888-570-6460

www.enzy.com

Acidophilus Pearls with patented True Delivery Technology 13e

82851